Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Enhanced memory responses to seasonal H1N1 influenza vaccination of the skin with the use of vaccine-coated microneedles.

Kim YC, Quan FS, Yoo DG, Compans RW, Kang SM, Prausnitz MR.

J Infect Dis. 2010 Jan 15;201(2):190-8. doi: 10.1086/649228.

2.

Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity.

Kim YC, Quan FS, Compans RW, Kang SM, Prausnitz MR.

J Control Release. 2010 Mar 3;142(2):187-95. doi: 10.1016/j.jconrel.2009.10.013. Epub 2009 Oct 17.

3.

Stabilization of influenza vaccine enhances protection by microneedle delivery in the mouse skin.

Quan FS, Kim YC, Yoo DG, Compans RW, Prausnitz MR, Kang SM.

PLoS One. 2009 Sep 25;4(9):e7152. doi: 10.1371/journal.pone.0007152.

4.

Development of an ex vivo human skin model for intradermal vaccination: tissue viability and Langerhans cell behaviour.

Ng KW, Pearton M, Coulman S, Anstey A, Gateley C, Morrissey A, Allender C, Birchall J.

Vaccine. 2009 Oct 9;27(43):5948-55. doi: 10.1016/j.vaccine.2009.07.088. Epub 2009 Aug 11.

5.
6.

Novel swine-origin influenza virus A (H1N1): the first pandemic of the 21st century.

Chang LY, Shih SR, Shao PL, Huang DT, Huang LM.

J Formos Med Assoc. 2009 Jul;108(7):526-32. doi: 10.1016/S0929-6646(09)60369-7. Review.

7.

A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.

Ross TM, Mahmood K, Crevar CJ, Schneider-Ohrum K, Heaton PM, Bright RA.

PLoS One. 2009 Jun 24;4(6):e6032. doi: 10.1371/journal.pone.0006032.

8.

Immunization by vaccine-coated microneedle arrays protects against lethal influenza virus challenge.

Zhu Q, Zarnitsyn VG, Ye L, Wen Z, Gao Y, Pan L, Skountzou I, Gill HS, Prausnitz MR, Yang C, Compans RW.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):7968-73. doi: 10.1073/pnas.0812652106. Epub 2009 Apr 27.

9.

Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

Zhang S, Cubas R, Li M, Chen C, Yao Q.

Mol Immunol. 2009 Jun;46(10):1988-2001. doi: 10.1016/j.molimm.2009.03.008. Epub 2009 Apr 18.

10.

Transdermal influenza immunization with vaccine-coated microneedle arrays.

Koutsonanos DG, del Pilar Martin M, Zarnitsyn VG, Sullivan SP, Compans RW, Prausnitz MR, Skountzou I.

PLoS One. 2009;4(3):e4773. doi: 10.1371/journal.pone.0004773. Epub 2009 Mar 10.

11.

Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

Kang SM, Yoo DG, Lipatov AS, Song JM, Davis CT, Quan FS, Chen LM, Donis RO, Compans RW.

PLoS One. 2009;4(3):e4667. doi: 10.1371/journal.pone.0004667. Epub 2009 Mar 2.

12.

Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes.

Cubas R, Zhang S, Kwon S, Sevick-Muraca EM, Li M, Chen C, Yao Q.

J Immunother. 2009 Feb-Mar;32(2):118-28. doi: 10.1097/CJI.0b013e31818f13c4.

13.

Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.

Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, Richardson C.

Vaccine. 2009 Jan 22;27(4):530-41. doi: 10.1016/j.vaccine.2008.11.011. Epub 2008 Nov 19.

PMID:
19026705
14.

Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.

Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y.

Vaccine. 2009 Jan 14;27(3):454-9. doi: 10.1016/j.vaccine.2008.10.077. Epub 2008 Nov 18.

PMID:
19022318
15.

Transdermal drug delivery.

Prausnitz MR, Langer R.

Nat Biotechnol. 2008 Nov;26(11):1261-8. doi: 10.1038/nbt.1504. Review.

16.

Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice.

Nicolas JF, Guy B.

Expert Rev Vaccines. 2008 Oct;7(8):1201-14. doi: 10.1586/14760584.7.8.1201. Review.

PMID:
18844594
17.

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, McKeirnan M, Salem H, Mills G, Reid J, Weber F, Saville M.

J Infect Dis. 2008 Sep 1;198(5):650-8. doi: 10.1086/590434.

PMID:
18652550
18.

Therapeutic human papillomavirus vaccines: current clinical trials and future directions.

Hung CF, Ma B, Monie A, Tsen SW, Wu TC.

Expert Opin Biol Ther. 2008 Apr;8(4):421-39. doi: 10.1517/14712598.8.4.421 . Review.

19.

Induction of heterosubtypic immunity to influenza virus by intranasal immunization.

Quan FS, Compans RW, Nguyen HH, Kang SM.

J Virol. 2008 Feb;82(3):1350-9. Epub 2007 Nov 21.

20.

Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults.

Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE.

Vaccine. 2007 Sep 17;25(37-38):6755-63. Epub 2007 Jul 26.

Supplemental Content

Support Center